Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians.
We believe an era of stalled innovation for pain management is over. From San Francisco to Singapore, our team has a passion for solving medical challenges that could benefit millions. We pursue our mission with the energy of a dynamic, global team of entrepreneurs, scientists, clinicians and innovators.
We believe an era of stalled innovation for pain management is over. From San Francisco to Singapore, our team has a passion for solving medical challenges that could benefit millions. We pursue our mission with the energy of a dynamic, global team of entrepreneurs, scientists, clinicians and innovators.
Location: United States, California, Menlo Park
Employees: 11-50
Total raised: $117.5M
Founded date: 2017
Investors 3
| Date | Name | Website |
| 29.12.2021 | New Enterp... | nea.com |
| - | Brandon Ca... | brandoncap... |
| 14.05.2021 | Lightstone... | lightstone... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 18.06.2025 | Series D | $57.5M | - |
| 16.09.2021 | Series C | $60M | Arboretum ... |
Mentions in press and media 12
| Date | Title | Description |
| 18.06.2025 | Lightstone Ventures, Temasek’s ClavystBio support Allay Therapeutics’ $57.5 M Series D funding | Clinical-stage biotechnology startup Allay Therapeutics said last Thursday that it had closed a $57.5 million Series D funding round with top international investors. According to a statement from the company, the Series D financing was co-... |
| 12.06.2025 | Allay Therapeutics: A New Dawn in Pain Management | Allay Therapeutics is on the brink of a revolution. The San Jose-based biotechnology company has raised $57.5 million in a Series D financing round. This funding is a lifeline for a company that aims to transform post-surgical pain manageme... |
| 11.06.2025 | Allay Therapeutics: $57.5 Million Funding Raised For Advancing ATX101 | Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recovery, announced the completion of a $57.5 million Series D financing round with lead... |
| 10.06.2025 | Allay Therapeutics Announces $57.5M Series D Financing and Venture Debt Line to Advance ATX101 and its Ultra-Sustained Pain Platform for Post-Surgical Pain Management | Series D led by Lightstone Ventures, ClavystBio and WTT investment, supported by leading global syndicate of new and existing investors; Venture debt funding led by HSBC Funds to advance ATX101 Phase 2b registration trial of post-surgical p... |
| 05.06.2025 | Allay Therapeutics Closes $57.5M Series D | SAN JOSE, CA, Allay Therapeutics today announced the completion of a $57.5 million Series D financing round. >> Click here for more funding data on Allay Therapeutics >> To export Allay Therapeutics funding data to PDF and Exce... |
| 05.06.2025 | Allay Therapeutics Raises $57.5M in Series D Financing and Venture Debt | Allay Therapeutics, a San Jose, CA-based clinical-stage biotechnology company providing ultra-sustained analgesic products for post-surgical pain management and recuperation, raised $57.5M in Series D financing. Lightstone Ventures and Clav... |
| 19.02.2025 | Allay Therapeutics Announces First Patients Dosed in Pivotal Phase 2b RegistrationTrial of ATX101 for Post-Surgical Pain Management After Knee Replacement Surgery | SAN JOSE, CA, February 18, 2024 (BUSINESSWIRE) – Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced that the ... |
| 15.09.2022 | ClavystBio launches to translate life sciences breakthroughs into health impact | ClavystBio will invest and work with partners to accelerate life sciences commercialisation in Singapore through three pillars: collaborate, venture and build. ClavystBio has committed US$220 million to date in investments to launch global ... |
| 16.09.2021 | Allay Therapeutics Completes Oversubscribed $60M Financing to Advance Ultra-Sustained Pain Platform | Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the completion of its oversubscribed $60M Series C financi... |
| 16.09.2021 | Allay Therapeutics Completes $60M Series C | MENLO PARK, CA, Allay Therapeutics, a clinical-stage biotechnology company, announced the completion of its oversubscribed $60M Series C financing. >> Click here for more funding data on Allay Therapeutics >> To export Allay... |
Show more